

CARDIOLOGY GRAND ROUNDS



CV Effects of Diabetes Medications: Lessons Learned from the Cardiovascular Outcome Trials

Darren McGuire, MD

University of Texas Southwestern Medical Center

September 14, 2018, 12:00 p.m.

**Denton A. Cooley Auditorium
Room C060**

Review the evolution of the regulatory requirements for drugs for type 2 diabetes, review the key findings from CV outcome trials completed to date and review selected potential mechanisms underpinning beneficial effects of SGLT2 inhibitors on CV mortality and heart failure risk.

At the conclusion of this conference, participants should be able to:

- Describe the regulatory history of drugs for diabetes and the background for the present requirement of such drugs to undergo formal trials assessment of CV safety.
- Review the key findings recently completed/ reported CV outcome trials of drugs for diabetes.
- Apply in practice the present cardiology and diabetes society recommendations and guidelines with respect use of diabetes drugs with proven CV efficacy.

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Texas Heart Institute designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Dr. McGuire has received Honoraria for Clinical Trials from AstraZeneca, Sanofi Aventis, Janssen, Boehringer Ingelheim, Merck & CO, Novo Nordisk, Lexicon, Eisai, GlaxoSmithKline and Esperion. Dr. McGuire has received Consultation fees from AstraZeneca, Sanofi Aventis, Lilly US, Boehringer Ingelheim, Merck & company Pfizer and Novo Nordisk.

The Planning Committee has nothing to disclose.

The THI CME Staff have nothing to disclose.

The Program Reviewers have nothing to disclose.